How to deal with the side effects of giritinib/segatan

Gilitinib/Gilteritinib is a targeted therapy for FLT3 mutated acute myeloid leukemia (AML). Although it has significant efficacy, it may still have a variety of side effects during clinical use, which requires close attention and management by doctors and patients. The most common adverse reactions include fever, fatigue, diarrhea, nausea, constipation and liver function abnormalities. Most of these side effects are mild to moderate and can be alleviated through symptomatic treatment or short-term dose adjustment.

Hematology-related side effects are more significant, such as neutropenia, thrombocytopenia, and anemia. Patients with moderate or severe cytopenias are usually managed with extended dosing intervals, temporary drug withdrawal, or supportive transfusion therapy. Monitoring of platelets and neutrophils is particularly important to prevent increased risk of infection and bleeding. For abnormal liver function, such as elevated ALT/AST or elevated bilirubin, liver function indicators should be monitored regularly, giritinib should be suspended if necessary, and the dose should be adjusted based on recovery.

Although the incidence of cardiovascular-related adverse reactions is low, QT interval prolongation and arrhythmia still require vigilance. In clinical practice, electrocardiogram monitoring is usually performed before medication and during treatment. When abnormalities are found, the dose can be adjusted or the medication discontinued in a timely manner. For gastrointestinal reactions, such as nausea, vomiting or diarrhea, anti-nausea drugs or fluid replacement support can be used to ensure the patient's quality of life.

In addition, giritinib may cause differentiation syndrome or tumor lysis syndrome in some patients. These side effects are rare but potentially serious and require early recognition. Treatment strategies usually include corticosteroids, antibiotic support, and fluid management with close monitoring of blood electrolyte changes.

In summary, the side effects of giritinib can be effectively managed through regular monitoring, dose adjustment, symptomatic treatment, and comprehensive supportive care. Clinicians need to develop a safe medication plan based on the patient's condition, and at the same time emphasize to patients and their families the importance of taking medications as prescribed and reporting abnormal symptoms to maximize efficacy and reduce risks.

Reference materials:https://www.xospata.com/